Archive for the ‘oncology retractions’ Category
When a group of authors decided to write up a curious case of a 35-year-old woman with a mysterious mass that took 11 years to be diagnosed, they tried repeatedly to contact the patient for her permission. When they couldn’t reach her, they published the paper anyway, removing any identifiable information.
But the report apparently included enough details for the patient to recognize herself — and when she read the paper, she asked the authors to retract it.
That’s the story according to the publisher of the 2016 case study, which recently retracted it with this notice:
Researchers in China have retracted a 2016 cancer imaging paper because they introduced “a plethora of data errors” while preparing the article for submission.
Although the retraction notice provides no details on what these errors are or how exactly they occurred, it does point the finger at the researchers, explaining that the data errors happened as a result of their “negligence.”
Here’s the 2017 retraction notice for “Rituximab-conjugated, doxorubicin-loaded microbubbles as a theranostic modality in B-cell lymphoma,” published November 25, 2016 in Oncotarget: Read the rest of this entry »
A journal has retracted six papers by a cancer researcher at the University of Maryland in Baltimore, bringing his total to 10.
The retractions cite an investigation by the university, and detail problems ranging from duplicated images, to tweaking an image to conceal particular bands, to including unreliable data.
Three of the papers had already been flagged by the journal with expressions of concern. The last author on all the papers is Anil Jaiswal, a professor in the pharmacology department. He has issued four previous retractions.
Bruce Jarrell, the Chief Academic and Research Officer and Senior Vice President at the University of Maryland, told us at least two more retractions are forthcoming:
Researchers in Ireland have retracted a case study about a rare type of cancer in a child because – contrary to what they claimed in the paper – they had not obtained the necessary permission from the parents.
In the June 2016 article, the authors stated they had received “written informed consent” from the parents to publish the case. But according to the retraction notice — issued just a few months later in October — that was not the case.
Here’s the retraction notice for “Paediatric Ewing-like sarcoma arising from the cranium – a unique diagnostic challenge,” which for legal reasons, the publisher has withdrawn from public view:
An oncology journal has retracted a 2014 paper that contained a potentially fatal mistake.
Specifically, the paper suggested that a chemotherapy drug be injected intrathecally — i.e., in the spine. But according to the retraction notice, the medical literature has unequivocally shown that that form of treatment is “uniformly fatal.”
The retraction comes approximately 18 months after the journal published a letter to the editor alerting readers to the risky wording in the 2014 paper.
Here’s the notice, issued by Hematological Oncology:
An oncology journal has decided to retract a 2012 paper on gastric cancer after discovering duplicated data in multiple figures.
According to the retraction notice, the journal’s editorial board received a tip from a reader regarding the potential figure issues. Oncology Reports launched an investigation, which confirmed the allegations. The authors failed to respond to the journal’s multiple requests for more information.
Zhao Kai, the study’s first author from the Qilu Hospital of Shandong University and Zibo Central Hospital (both in China), took full responsibility for the error.
According to the retraction notice in the International Journal of Molecular Medicine, the reader showed the journal that the histological data in two of the figures were from another published paper by different researchers. But when the journal contacted the authors on several occasions, they didn’t hear back.
Researchers have retracted their third paper due to missing original data, following an investigation at their former institution in New York.
We’ve previously reported on two retractions of papers co-authored by Bhagavathi Narayanan and Narayanan K. Narayanan, previously based at the New York University (NYU) School of Medicine. The studies were pulled when the pair couldn’t provide original images to investigators at NYU School of Medicine. One author has blamed the lack of original data on the abrupt closure of her previous institution in 2004, after it allegedly misspent millions in federal grants.
However, the latest retraction affects a paper published eight years later in the International Journal of Oncology. Its coauthors include Bhagavathi Narayanan, Narayanan K. Narayanan and Rajkishen Narayanan; we haven’t been able to uncover if there is a relation between them.
A spokesperson for the NYU School of Medicine sent us this statement: Read the rest of this entry »
The paper was published in March, 2015 — the same month publisher BioMed Central (BMC) pulled 43 papers for fake reviews.
According to the retraction notice in the European Journal of Medical Research, the authors’ institution in China informed the publisher that the authors had used a third party to help with copyediting and submission to the journal, raising concerns about the authorship of the paper.